[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Plotnikov A, Tichler T, Korenstein R, Keisari Y: Involvement of the immune response in the cure of metastatic murine CT-26 colon carcinoma by low electric field-enhanced chemotherapy. Int J Cancer; 2005 Dec 10;117(5):816-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of the immune response in the cure of metastatic murine CT-26 colon carcinoma by low electric field-enhanced chemotherapy.
  • Low electric field cancer treatment-enhanced chemotherapy (LEFCT-EC) is a new treatment modality that combines chemotherapeutic agents and low electric field stimulation.
  • LEFCT-EC was found to destroy malignant mouse tumors and cause massive death of tumor cells.
  • This may enable the immune system cells to efficiently recognize and eliminate tumor cells at the primary tumor site and at metastatic foci.
  • Mice with 15 mm diameter intracutaneous colon carcinomas (CT-26) were injected with BCNU (35 mg/kg), and 2 min later the tumors were exposed to low electric fields (intensity 40 V/cm, pulse duration 180 micros, frequency 500 Hz) for 12 min (LEFCT-EC).
  • We found that treatment with LEFCT-EC achieved complete cure of 93% of the animals.
  • In comparison, electric fields alone (13% cure), chemotherapy alone (0%), surgery (15%) or a combination of surgery and bis-chloroethyl-nitrosurea, carmustine (BCNU; 84%) treatments resulted in lower cure rates.
  • After treatment and cure with LEFCT-EC, 50% of the cured mice developed resistance to a tumor challenge (surgery + BCNU only 15%).
  • Furthermore, splenocytes from cured animals protected naive animals from a tumorigenic dose of tumor cells.
  • FACS analysis revealed restoration of normal splenocyte subpopulation proportions impaired by cytotoxic chemotherapy.
  • Our results suggest that LEFCT-EC can directly destroy primary tumors and facilitate the destruction of metastatic disease by enforcement of antitumor immune responses.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Carmustine / therapeutic use. Colonic Neoplasms / immunology
  • [MeSH-minor] Animals. Cell Line, Tumor. Flow Cytometry. Mice. Mice, Inbred BALB C. Neoplasm Metastasis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15981217.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; U68WG3173Y / Carmustine
  •  go-up   go-down


2. Osei DA, Alvandi F, Brooks JS, Ogilvie CM: PEComa of the Upper Extremity: A Unique Case and Description of an Initial Response to Neoadjuvant Chemotherapy. Sarcoma; 2007;2007:53056
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PEComa of the Upper Extremity: A Unique Case and Description of an Initial Response to Neoadjuvant Chemotherapy.
  • Purpose. Tumors of the perivascular epithelial cell tumor (PEComa), first described in 1992, represent a rare soft tissue neoplasm of varying malignant potential.
  • To date, most malignant cases of PEComa have been resistant to chemotherapy, and as such, an appropriate therapy is not known.
  • Open biopsy revealed a high-grade malignant lesion, and the patient subsequently underwent both neoadjuvant therapy with doxorubicin, ifosfamide and mensa, and radiation therapy prior to wide surgical resection.
  • After six cycles of chemotherapy, the tumor underwent an 80% reduction in size.
  • Subsequent neoadjuvant radiation therapy of 5000 cGy did not further reduce the size of the tumor.
  • Following limb sparing radical resection, pathology showed 20% necrosis within a high-grade malignant lesion.
  • Twenty one months after beginning treatment, the patient shows no sign of local recurrence, but metastatic disease was confirmed after resection of a lung nodule.
  • Conclusion. Given the favorable albeit partial response seen in this patient, the course of therapy outlined here may represent a good starting point for neoadjuvant treatment in a tumor with a historically bleak prognosis.
  • In addition, the diagnosis of PEComa must now be entertained in the differential diagnosis of upper extremity soft tissue sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 1999 Jul;11(4):285-95 [10416881.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1238-47 [11230464.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):121-6 [11145246.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):563-8 [11406657.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3203-9 [11432887.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):809-12 [12023589.001]
  • [Cites] Int J Urol. 2003 May;10(5):271-3 [12694468.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):677-81 [13678746.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1230-2 [15316324.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):1-7 [15486953.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1667-72 [15520069.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1734-7 [15540307.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Jun;19(3):489-500, vi [15939193.001]
  • [Cites] Pathology. 1994 Jul;26(3):230-6 [7991275.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1239-46 [10976698.001]
  • (PMID = 18274609.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2225462
  •  go-up   go-down


3. Zlobec I, Lugli A: Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget; 2010 Nov;1(7):651-61
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget.
  • Epithelial mesenchymal transition (EMT) is proposed as a critical mechanism for the acquisition of malignant phenotypes by epithelial cells.
  • In colorectal cancer, tumor cells having undergone EMT are histologically represented by the presence of tumor buds defined as single cells or small clusters of de-differentiated tumor cells at the invasive front.
  • Tumor budding is not a static, histological feature rather it represents a snap-shot of a dynamic process undertaken by an aggressive tumor with the potential to disseminate and metastasize.
  • Strong, consistent evidence shows that tumor budding is a predictor of lymph node metastasis, distant metastatic disease, local recurrence, worse overall and disease-free survival time and an independent prognostic factor.
  • Moreover, the International Union against Cancer (UICC) recognizes tumor budding as a highly relevant, additional prognostic parameter.
  • The aim of this review is to summarize the evidence supporting the implementation of tumor budding into diagnostic pathology and patient management and additionally to illustrate its worthiness as a potential therapeutic target.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma / pathology. Colorectal Neoplasms / pathology. Epithelial-Mesenchymal Transition / physiology. Molecular Targeted Therapy / methods. Pseudopodia / drug effects
  • [MeSH-minor] Animals. Humans. Microsatellite Instability. Models, Biological. Neoplasm Invasiveness. Prognosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2006;202(9):663-70 [16860493.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1422-30 [16767517.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9543-56 [17018611.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1059-64 [16940750.001]
  • [Cites] Histopathology. 2007 Jan;50(1):151-62 [17204028.001]
  • [Cites] Eur J Cancer. 2007 Feb;43(3):624-31 [17223543.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):221-32 [17361206.001]
  • [Cites] J Pathol. 2007 Jul;212(3):260-8 [17516584.001]
  • [Cites] Pathology. 2007 Jun;39(3):305-18 [17558857.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):863-8 [17216219.001]
  • [Cites] Cells Tissues Organs. 2007;185(1-3):29-39 [17587805.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1597-602 [15937624.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):48-56 [17631130.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):386-95 [17600130.001]
  • [Cites] J Clin Pathol. 2007 Aug;60(8):912-5 [16997919.001]
  • [Cites] Dis Colon Rectum. 2007 Sep;50(9):1370-6 [17661146.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6871s-6s [18006792.001]
  • [Cites] Colorectal Dis. 2008 Jan;10(1):41-7 [18078460.001]
  • [Cites] Dis Colon Rectum. 2008 May;51(5):568-72 [18286339.001]
  • [Cites] Anticancer Res. 2008 May-Jun;28(3B):1773-8 [18630458.001]
  • [Cites] Anticancer Res. 2008 May-Jun;28(3B):1831-6 [18630467.001]
  • [Cites] Anticancer Res. 2008 Jul-Aug;28(4C):2417-20 [18751428.001]
  • [Cites] Int J Oncol. 2009 Jan;34(1):53-60 [19082477.001]
  • [Cites] J Pathol. 2009 Jan;217(2):307-17 [19031475.001]
  • [Cites] Am J Surg Pathol. 2009 Jan;33(1):134-41 [18971777.001]
  • [Cites] Virchows Arch. 2009 May;454(5):541-8 [19360438.001]
  • [Cites] J Clin Invest. 2009 Jun;119(6):1417-9 [19487817.001]
  • [Cites] J Clin Invest. 2009 Jun;119(6):1420-8 [19487818.001]
  • [Cites] Jpn J Clin Oncol. 2002 Oct;32(10):412-6 [12451038.001]
  • [Cites] Clin Colorectal Cancer. 2002 Nov;2(3):149-60 [12482331.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):69-73 [12499439.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45 [12511867.001]
  • [Cites] Dig Dis Sci. 2003 Feb;48(2):272-8 [12643602.001]
  • [Cites] Am J Clin Pathol. 2009 Aug;132(2):202-10; quiz 307 [19605814.001]
  • [Cites] J Transl Med. 2009;7:56 [19583834.001]
  • [Cites] Nat Protoc. 2009;4(11):1591-613 [19834475.001]
  • [Cites] Histopathology. 2009 Nov;55(5):564-75 [19912362.001]
  • [Cites] Hum Pathol. 2010 Jan;41(1):70-8 [19740518.001]
  • [Cites] World J Gastroenterol. 2009 Dec 21;15(47):5898-906 [20014453.001]
  • [Cites] World J Gastroenterol. 2010 Feb 14;16(6):732-9 [20135722.001]
  • [Cites] Dis Colon Rectum. 2010 Mar;53(3):301-7 [20173477.001]
  • [Cites] Gastroenterology. 2010 Apr;138(4):1406-17 [20026115.001]
  • [Cites] Carcinogenesis. 2010 Apr;31(4):597-606 [20118200.001]
  • [Cites] J Cell Sci. 2010 Apr 15;123(Pt 8):1295-305 [20332115.001]
  • [Cites] PLoS One. 2010;5(4):e10221 [20421926.001]
  • [Cites] Int J Biochem Cell Biol. 2010 Jun;42(6):911-20 [20109579.001]
  • [Cites] Oncogene. 2010 Jun 17;29(24):3490-500 [20418909.001]
  • [Cites] Am J Clin Pathol. 2010 Aug;134(2):312-22 [20660337.001]
  • [Cites] Mod Pathol. 2010 Aug;23(8):1068-72 [20473277.001]
  • [Cites] Histopathology. 2010 Aug;57(2):233-43 [20716165.001]
  • [Cites] J Surg Oncol. 2010 Sep 1;102(3):235-41 [20740581.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Jul;21(7):1115-21 [16824062.001]
  • [Cites] Int J Cancer. 2011 Mar 1;128(5):1080-94 [20473920.001]
  • [Cites] Int J Cancer. 2011 May 1;128(9):2031-7 [20635387.001]
  • [Cites] Histopathology. 2011 Sep;59(3):482-95 [22034888.001]
  • [Cites] World J Gastroenterol. 2010 Oct 14;16(38):4823-31 [20939111.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1317-21 [11355941.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10356-61 [11526241.001]
  • [Cites] Jpn J Cancer Res. 2001 Oct;92(10):1074-81 [11676858.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1613-7 [11696421.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2539-46 [11745187.001]
  • [Cites] Histopathology. 2002 Feb;40(2):127-32 [11952856.001]
  • [Cites] J Surg Oncol. 2003 May;83(1):42-7 [12722096.001]
  • [Cites] Dig Dis Sci. 2003 Jul;48(7):1262-7 [12870781.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1054-9 [12907899.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2898-903 [12912934.001]
  • [Cites] Int J Oncol. 2003 Oct;23(4):1009-13 [12963980.001]
  • [Cites] Br J Surg. 2004 Mar;91(3):327-33 [14991634.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):385-94 [15300569.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):832-9 [15492565.001]
  • [Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]
  • [Cites] J Clin Pathol. 1986 Jun;39(6):585-9 [3722412.001]
  • [Cites] Cancer. 1989 Feb 1;63(3):539-43 [2912530.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):627-35 [8348847.001]
  • [Cites] Dis Colon Rectum. 1995 Jan;38(1):19-26 [7813339.001]
  • [Cites] J Pathol. 1995 Jun;176(2):151-9 [7636625.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):4132-9 [7664291.001]
  • [Cites] Oncogene. 1997 Mar 20;14(11):1329-40 [9178893.001]
  • [Cites] Hum Pathol. 1998 Jun;29(6):627-35 [9635685.001]
  • [Cites] Gut. 1998 May;42(5):673-9 [9659163.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1603-8 [9990071.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Oct;14(10):1004-9 [10530497.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] World J Gastroenterol. 2005 Feb 28;11(8):1193-5 [15754403.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):893-8 [15821121.001]
  • [Cites] Ann Oncol. 2005 May;16 Suppl 4:iv74-79 [15923435.001]
  • [Cites] Cells Tissues Organs. 2005;179(1-2):56-65 [15942193.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1182-92 [15793641.001]
  • [Cites] Histopathology. 2005 Jul;47(1):17-24 [15982319.001]
  • [Cites] Histopathology. 2005 Jul;47(1):25-31 [15982320.001]
  • [Cites] J Surg Oncol. 2005 Oct 1;92(1):59-63 [16180229.001]
  • [Cites] Hepatogastroenterology. 2005 Sep-Oct;52(65):1432-5 [16201089.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2B):1589-94 [16619576.001]
  • [Cites] Hum Pathol. 2006 May;37(5):578-85 [16647956.001]
  • [Cites] Eur J Cancer. 2006 May;42(7):964-71 [16563744.001]
  • [Cites] Hum Pathol. 2006 Aug;37(8):1022-31 [16867865.001]
  • (PMID = 21317460.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC3248128
  •  go-up   go-down


Advertisement
4. Caron JM, Bannon M, Rosshirt L, Luis J, Monteagudo L, Caron JM, Sternstein GM: Methyl sulfone induces loss of metastatic properties and reemergence of normal phenotypes in a metastatic cloudman S-91 (M3) murine melanoma cell line. PLoS One; 2010;5(8):e11788
Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methyl sulfone induces loss of metastatic properties and reemergence of normal phenotypes in a metastatic cloudman S-91 (M3) murine melanoma cell line.
  • BACKGROUND: The most deadly form of cancer is not lung or colon, breast or prostate; it is any cancer that has become metastatic.
  • Mortality due to metastatic melanoma, one of the most aggressive and deadly cancers, has increased steadily over the last several decades.
  • We sought to identify an effective and nontoxic agent against metastatic melanoma.
  • METHODOLOGY/PRINCIPAL FINDINGS: We chose to study Cloudman S-91 mouse melanoma cells (sub-clone M3, CCL53.1) because these cells are highly aggressive and metastatic, representing one of the deadliest types of cancer.
  • Melanoma cells also had an experimental advantage because their morphology, which is easily monitored, relates to the physiology of metastatic cells and normal melanocytes.
  • Surprisingly, we found that malignant melanoma cells exposed to methyl sulfone demonstrated the loss of phenotypes characteristic of malignant cells, and the reemergence of phenotypes characteristic of healthy melanocytes.
  • Briefly, over time methyl sulfone induced contact inhibition, loss of ability to migrate through an extracellular matrix, loss of anchorage-independent growth, proper wound healing followed by contact inhibition, irreversible senescence followed by arborization with melanosomes in arbors as seen in normal melanocytes.
  • CONCLUSIONS/SIGNIFICANCE: Methyl sulfone may have clinical potential as a non-toxic agent effective against metastatic melanoma.
  • Additionally, methyl sulfone has promise as a tool to explore molecular mechanisms of metastatic transformation as well as fundamental processes such as cell migration, contact inhibition, wound healing and cellular senescence.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Dimethyl Sulfoxide / pharmacology. Melanoma, Experimental / pathology. Neoplasm Metastasis / drug therapy. Phenotype. Sulfones / pharmacology
  • [MeSH-minor] Animals. Cell Aging / drug effects. Cell Line, Tumor. Cell Movement / drug effects. Extracellular Matrix / drug effects. Extracellular Matrix / metabolism. Melanocytes / cytology. Melanocytes / drug effects. Mice. Time Factors. Wound Healing / drug effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1965 Nov;27(2):273-9 [5884626.001]
  • [Cites] J Clin Oncol. 2009 Dec 20;27(36):6199-206 [19917835.001]
  • [Cites] Brain Res. 1977 Jan 21;120(2):287-301 [64281.001]
  • [Cites] CA Cancer J Clin. 1983 Mar-Apr;33(2):122-5 [6186349.001]
  • [Cites] Urol Res. 1988;16(4):329-31 [3176208.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1704-9 [2224119.001]
  • [Cites] Urol Res. 1992;20(3):233-6 [1615585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1253-5 [8640809.001]
  • [Cites] Dev Biol. 1996 Dec 15;180(2):445-54 [8954717.001]
  • [Cites] Cell. 1997 Mar 7;88(5):593-602 [9054499.001]
  • [Cites] Magn Reson Imaging. 2000 Jan;18(1):95-8 [10642107.001]
  • [Cites] J Altern Complement Med. 2002 Apr;8(2):167-73 [12006124.001]
  • [Cites] Food Chem Toxicol. 2002 Oct;40(10):1459-62 [12387309.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2705-15 [12782571.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):481-92 [15170450.001]
  • [Cites] Oncogene. 1998 Oct 15;17(15):1923-30 [9788435.001]
  • [Cites] Am J Hematol. 1999 Feb;60(2):87-93 [9929098.001]
  • [Cites] Int J Biochem Cell Biol. 2005 May;37(5):961-76 [15743671.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Ernst Schering Res Found Workshop. 2005;(54):1-13 [16080283.001]
  • [Cites] Cell. 2007 Jul 27;130(2):223-33 [17662938.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):737-49 [17891189.001]
  • [Cites] Mol Cancer. 2009;8:3 [19133111.001]
  • [Cites] Neuron Glia Biol. 2008 Feb;4(1):27-34 [19006599.001]
  • [Cites] Nature. 1967 Jul 8;215(5097):171-2 [6049107.001]
  • (PMID = 20694196.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Sulfones; 9H4PO4Z4FT / dimethyl sulfone; YOW8V9698H / Dimethyl Sulfoxide
  • [Other-IDs] NLM/ PMC2915910
  •  go-up   go-down


5. Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WT, de Vries EG, Sleijfer DT: Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev; 2000 Dec;26(6):429-47

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term chemotherapy-related cardiovascular morbidity.
  • As a consequence of the successful use of chemotherapy in the treatment of curable neoplasms such as germ cell tumours and malignant lymphomas, and the increasing application of primary and adjuvant chemotherapy for various tumour types, the number of patients with a prolonged life expectancy after treatment is rising.
  • In this review we evaluate the literature on long-term cardiovascular toxicity related to chemotherapy in adult patients.
  • Two categories of patient with favourable life expectancy have been reviewed, namely patients cured of metastatic disease by chemotherapy and patients treated with adjuvant chemotherapy.
  • In the first category, the literature on long-term cardiovascular morbidity in survivors of metastatic testicular cancer and lymphomas is discussed, while in the second category this is done for patients treated with adjuvant chemotherapy for breast and colon cancer.
  • As well as the direct toxic effects of chemotherapy on the cardiovascular system, the indirect toxic effects such as chemotherapy-related metabolic changes that may cause cardiovascular morbidity are also discussed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cardiovascular Diseases / chemically induced
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Chemotherapy, Adjuvant. Colonic Neoplasms / drug therapy. Female. Humans. Lymphoma / drug therapy. Male. Morbidity. Neoplasm Metastasis. Testicular Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 11139373.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] ENGLAND
  • [Number-of-references] 191
  •  go-up   go-down


6. Lloyd JM, McIver CM, Stephenson SA, Hewett PJ, Rieger N, Hardingham JE: Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin Cancer Res; 2006 Jan 15;12(2):417-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells.
  • PURPOSE: Colorectal cancer patients diagnosed with stage I or II disease are not routinely offered adjuvant chemotherapy following resection of the primary tumor.
  • However, up to 10% of stage I and 30% of stage II patients relapse within 5 years of surgery from recurrent or metastatic disease.
  • The aim of this study was to determine if tumor-associated markers could detect disseminated malignant cells and so identify a subgroup of patients with early-stage colorectal cancer that were at risk of relapse.
  • Immunobead reverse transcription-PCR of five tumor-associated markers (carcinoembryonic antigen, laminin gamma2, ephrin B4, matrilysin, and cytokeratin 20) was used to detect the presence of colon tumor cells in peripheral blood and within the peritoneal cavity of colon cancer patients perioperatively.
  • A multivariate Cox proportional hazards regression analysis was done to determine whether detection of tumor cells was an independent prognostic marker for disease relapse.
  • RESULTS: Overall, 41 of 125 (32.8%) early-stage patients were positive for disseminated tumor cells.
  • [MeSH-major] Biomarkers, Tumor / blood. Colorectal Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascitic Fluid / pathology. Carcinoembryonic Antigen / blood. Carcinoembryonic Antigen / genetics. Female. Humans. Keratin-20. Keratins / blood. Keratins / genetics. Laminin / blood. Laminin / genetics. Male. Matrix Metalloproteinase 7 / blood. Matrix Metalloproteinase 7 / genetics. Middle Aged. Neoplasm Staging. Peritoneal Lavage. Prognosis. RNA, Messenger / analysis. Receptors, Eph Family / blood. Receptors, Eph Family / genetics. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428481.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / LAMC2 protein, human; 0 / Laminin; 0 / RNA, Messenger; 68238-35-7 / Keratins; EC 2.7.10.1 / Receptors, Eph Family; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


7. Pahlavan PS, Kanthan R: Goblet cell carcinoid of the appendix. World J Surg Oncol; 2005 Jun 20;3:36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Goblet cell carcinoid (GCC) of the appendix is a rare neoplasm that share histological features of both adenocarcinoma and carcinoid tumor.
  • While its malignant potential remains unclear, GCC's are more aggressive than conventional carcinoid.
  • The clinical presentations of this neoplasm are also varied.
  • The focus is on its diagnosis, histopathological aspects, clinical manifestations, and management.
  • Accurate diagnosis of this neoplasm requires astute observations within an acutely inflamed appendix as this neoplasm has a prominent pattern of submucosal growth and usually lacks the formation of a well-defined tumor mass.
  • The mesoappendix was involved in 21.64% followed by perineural involvement in 2.06%.
  • The most common surgical treatment of choice was appendectomy with right hemicolectomy in 34.70% followed by simple appendectomy in 24.57%.
  • Concomitant distant metastasis at diagnosis was present in 11.16% of patients with the ovaries being the most common site in 3.60% followed by disseminated abdominal carcinomatosis in 1.03%.
  • Local lymph node involvement was seen in 8.76% of patients at the time of diagnosis.
  • GCC's of the appendix remains a neoplasm of unpredictable biological behavior and thus warrants lifelong surveillance for recurrence of the disease upon diagnosis and successful surgical extirpation.
  • CONCLUSION: GCC of the appendix is a rare neoplasm.
  • Due to its wide range of presentation, this tumor should be considered as a possible diagnosis in many varied situations leading to abdominal surgery.
  • The advocated plan of management recommended for patients with tumors that involve the adjacent caecum or with high-grade tumors with histological features such as an increased mitotic rate involve initial appendectomy with completion right hemicolectomy due to the high possibility of local recurrence with intraperitoneal seeding prior to lymph node involvement and a 20% risk of metastatic behavior.
  • In cases with obvious spread of the disease chemotherapy, mostly with 5-FU and leucovorin is advised.
  • Cytoreductive surgery with adjuvant intraperitoneal chemotherapy can offer improved survival in cases with advanced peritoneal dissemination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1987 Feb;30(2):112-5 [3803115.001]
  • [Cites] Cancer. 1974 Mar;33(3):770-7 [4815580.001]
  • [Cites] Cancer. 1974 Aug;34(2):338-44 [4852178.001]
  • [Cites] Cancer. 1979 Nov;44(5):1700-6 [498041.001]
  • [Cites] Pathol Res Pract. 1984 Jul;178(6):555-61 [6483683.001]
  • [Cites] Gastroenterology. 1984 Feb;86(2):302-9 [6690357.001]
  • [Cites] Hum Pathol. 1982 Mar;13(3):286-8 [7076213.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):188-9 [7102895.001]
  • [Cites] Acta Obstet Gynecol Scand. 1982;61(2):153-6 [7113691.001]
  • [Cites] Diagn Gynecol Obstet. 1980 Winter;2(4):269-74 [7215111.001]
  • [Cites] Am J Surg Pathol. 1981 Apr;5(3):213-24 [7235117.001]
  • [Cites] Cancer. 1978 Dec;42(6):2687-95 [728868.001]
  • [Cites] Cancer. 1978 Dec;42(6):2781-93 [728874.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;386(2):201-10 [7368563.001]
  • [Cites] Acta Morphol Acad Sci Hung. 1980;28(1-2):37-58 [7446221.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):869-70 [7490325.001]
  • [Cites] Diagn Cytopathol. 1995 Feb;12(1):59-61 [7789249.001]
  • [Cites] Intern Med. 1994 Jul;33(7):422-6 [7949643.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):685-7 [7978019.001]
  • [Cites] J Clin Pathol. 1977 May;30(5):473-80 [864014.001]
  • [Cites] Histopathology. 1995 Dec;27(6):557-62 [8838336.001]
  • [Cites] Int J Gynecol Pathol. 1996 Jan;15(1):85-8 [8852453.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):109-13 [8990147.001]
  • [Cites] Arch Pathol Lab Med. 1976 Jun;100(6):301-6 [946758.001]
  • [Cites] J Gastroenterol. 1998 Aug;33(4):582-7 [9719248.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 [10363895.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):14-21 [10391558.001]
  • [Cites] Eur J Surg. 1999 Oct;165(10):993-7 [10574110.001]
  • [Cites] Surg Today. 2000;30(1):78-81 [10648090.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):386-90 [11231488.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):557-68 [11342766.001]
  • [Cites] Pathol Int. 2001 Apr;51(4):283-7 [11350611.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2001 Jul;97(1):90-5 [11435017.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):140-6 [11884049.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):47-58 [12114750.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3307-12 [12115365.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):551-64 [12163380.001]
  • [Cites] Dig Dis Sci. 2002 Dec;47(12):2760-2 [12498298.001]
  • [Cites] Histopathology. 2003 Feb;42(2):137-40 [12558745.001]
  • [Cites] Surg Today. 2003;33(5):375-8 [12734735.001]
  • [Cites] Radiographics. 2003 May-Jun;23(3):645-62 [12740466.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1317-22 [14598408.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1189-98 [14681318.001]
  • [Cites] Eur J Surg Oncol. 1992 Aug;18(4):386-7 [1521632.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1168-73 [15449269.001]
  • [Cites] Diagn Cytopathol. 1991;7(2):155-7 [1648469.001]
  • [Cites] Histopathology. 1991 Jan;18(1):61-5 [1672861.001]
  • [Cites] Leber Magen Darm. 1991 Sep;21(5):226,229-30 [1758238.001]
  • [Cites] Br J Urol. 1976 Dec;48(6):436 [188508.001]
  • [Cites] Acta Pathol Jpn. 1991 Jun;41(6):455-60 [1950561.001]
  • [Cites] Am J Clin Pathol. 1990 Jul;94(1):27-35 [2163192.001]
  • [Cites] Arch Pathol Lab Med. 1979 Apr;103(4):180-2 [218519.001]
  • [Cites] Gut. 1990 Mar;31(3):322-4 [2323597.001]
  • [Cites] Gut. 1990 Jul;31(7):840 [2370022.001]
  • [Cites] Int Surg. 1989 Apr-Jun;74(2):109-10 [2753618.001]
  • [Cites] J Surg Oncol. 1988 Jan;37(1):65-71 [2826924.001]
  • [Cites] Arch Pathol Lab Med. 1985 Oct;109(10):930-3 [2994592.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;412(2):175-82 [3122418.001]
  • [Cites] Surg Gynecol Obstet. 1988 Jul;167(1):81-6 [3289135.001]
  • [Cites] Dis Colon Rectum. 1988 Aug;31(8):605-12 [3402286.001]
  • (PMID = 15967038.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1182398
  •  go-up   go-down


8. Melmed GY, Devlin SM, Vlotides G, Dhall D, Ross S, Yu R, Melmed S: Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitis. Clin Gastroenterol Hepatol; 2008 Mar;6(3):360-3
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitis.
  • METHODS: We report the case of a 68-year-old man with colonic Crohn's disease who was found to have aggressive metastatic colon cancer.
  • The patient had been receiving HGH therapy for anti-aging purposes for 7 years before presentation.
  • Normal and malignant colonic tissue was examined for qualitative and quantitative molecular profiles of growth hormone (GH) and its signaling molecules, using immunohistochemistry and RNA extraction with polymerase chain reaction amplification.
  • RESULTS: Immunoreactivity was more robust in tumor tissue than in normal colon for insulin-like growth factor-1 receptor (IGF-1R) but not for IGF, GH, or GH receptor.
  • RNA extraction with quantitative polymerase chain reaction showed that IGF-1R and vascular endothelial growth factor expression, but not IGF-1, GH receptor, or suppressor of cytokine signaling-2, were higher in tumor than in normal colonic tissue.
  • CONCLUSIONS: Colorectal cancer development concurrent with administration of HGH for anti-aging purposes occurred in an individual already at increased risk for colon cancer.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2002 Jul 27;360(9329):273-7 [12147369.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1030-5 [11861378.001]
  • [Cites] J Nutr. 2001 Nov;131(11 Suppl):3109S-20S [11694656.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600 [11018095.001]
  • [Cites] N Engl J Med. 2000 Jun 1;342(22):1633-7 [10833209.001]
  • [Cites] J Biol Chem. 1996 Nov 15;271(46):29483-8 [8910616.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):620-5 [10203281.001]
  • [Cites] Inflamm Bowel Dis. 2004 Nov;10(6):871-80 [15626905.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:108-15 [15761242.001]
  • [Cites] JAMA. 2005 Oct 26;294(16):2086-90 [16249424.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1632-41 [16410303.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Mar;2(3):119 [16932266.001]
  • [Cites] Gastroenterol Clin North Am. 2006 Sep;35(3):553-71 [16952740.001]
  • [Cites] Ann Intern Med. 2007 Jan 16;146(2):104-15 [17227934.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5351-2 [12466319.001]
  • [Cites] N Engl J Med. 2003 Feb 27;348(9):779-80 [12606731.001]
  • [Cites] N Engl J Med. 2003 Jul 24;349(4):350-7 [12878742.001]
  • [Cites] Endocr Pract. 2003 Jan-Feb;9(1):64-76 [12917095.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):570-81 [15300589.001]
  • [Cites] Int J Cancer. 1994 Aug 1;58(3):452-9 [8050827.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2086-95 [12412161.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):659 [7993846.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1128-33 [10534157.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):345-9 [10794477.001]
  • [Cites] Lab Invest. 2002 Oct;82(10):1377-89 [12379772.001]
  • [Cites] Gut. 2002 Oct;51 Suppl 5:V13-4 [12221033.001]
  • (PMID = 18255351.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075979-10; United States / NCI NIH HHS / CA / R01 CA075979; United States / NIDDK NIH HHS / DK / T32 DK007180; United States / NCI NIH HHS / CA / R01 CA075979-10
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 12629-01-5 / Human Growth Hormone
  • [Other-IDs] NLM/ NIHMS54361; NLM/ PMC2696478
  •  go-up   go-down


9. Azab AK, Kleinstern J, Srebnik M, Rubinstein A: The metastatic stage-dependent mucosal expression of sialic acid is a potential marker for targeting colon cancer with cationic polymers. Pharm Res; 2008 Feb;25(2):379-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The metastatic stage-dependent mucosal expression of sialic acid is a potential marker for targeting colon cancer with cationic polymers.
  • PURPOSE: Locoregional recurrence is the most common complication after adenocarcinoma resection in the colon, despite adjuvant chemotherapy.
  • Therapy efficacy could be improved if designed to target malignant cells by incorporating specific recognition factors in the drugs or the drug vehicles.
  • The aim of this study was to elucidate whether the overexpression of sialic acid (SA) on colonic malignant tissues could be utilized for drug targeting by cationic polymers.
  • MATERIALS AND METHODS: Cell lines (IEC-6, SW-480 and SW-620) and colon polyps and normal adjacent tissues harvested from dimethylhydrazine (DMH) induced rats were used as in vitro and in vivo models of different metastatic stages of colon cancer.
  • The binding of FITC labeled cationic polymers of various degrees of cationization to normal and malignant colonic cells and tissue was measured.
  • RESULTS: SA was overexpressed on malignant colonic cells and tissues, and its expression correlated to the metastatic stage in vitro.
  • The binding of the cationic copolymers to the cell lines and tissues correlated with the charge density of the polymer and with the metastatic stage of the cell line.
  • The interaction between the malignant colonic cells and tissues with the polymers was SA dependent and increased after mucus removal.
  • CONCLUSION: Cationic polymers could be used as a targeting tool to colonic malignant epithelium, to be implemented in drug delivery and diagnosis.
  • [MeSH-major] Acrylamides / pharmacology. Colonic Neoplasms / drug therapy. N-Acetylneuraminic Acid / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Intestinal Mucosa / metabolism. Neoplasm Metastasis. Neoplasm Staging. Rats. Wheat Germ Agglutinins / metabolism

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pharm. 2003 Nov 28;267(1-2):1-12 [14602379.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Mar;21(3):563-8 [16638099.001]
  • [Cites] FASEB J. 1997 Mar;11(4):248-55 [9068613.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):343-8 [16527698.001]
  • [Cites] Eur J Histochem. 1993;37(3):257-65 [7693064.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):609-36 [15722167.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6831-6 [12460895.001]
  • [Cites] Cancer Res. 1995 Apr 15;55(8):1675-9 [7712474.001]
  • [Cites] Nature. 2006 May 25;441(7092):451-6 [16724057.001]
  • [Cites] Gastrointest Endosc. 2004 May;59(6):634-41 [15114305.001]
  • [Cites] Cancer Cell Int. 2006 Jun 23;6:17 [16792817.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):727-35 [8625173.001]
  • [Cites] Cancer Lett. 1993 Dec 20;75(3):143-9 [8313349.001]
  • [Cites] Annu Rev Biomed Eng. 1999;1:241-63 [11701489.001]
  • [Cites] J R Soc Med. 1983 Jun;76(6):467-72 [6864720.001]
  • [Cites] Cell Biol Int Rep. 1990 Mar;14(3):275-86 [2344628.001]
  • [Cites] J Neurooncol. 1986;4(1):23-9 [3746382.001]
  • [Cites] J Clin Invest. 1987 Nov;80(5):1245-54 [2890655.001]
  • [Cites] Biochemistry. 1979 Nov 27;18(24):5505-11 [92996.001]
  • [Cites] Surg Oncol Clin N Am. 2006 Jan;15(1):147-57 [16389155.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1482-7 [17244708.001]
  • [Cites] J Control Release. 2005 Aug 18;106(1-2):14-25 [16005094.001]
  • [Cites] Science. 1983 Aug 12;221(4611):673-5 [6603020.001]
  • [Cites] Acta Physiol Hung. 1994;82(1):3-13 [7976394.001]
  • [Cites] Rev Esp Fisiol. 1997 Dec;53(4):385-6 [9580472.001]
  • [Cites] J Histochem Cytochem. 2004 May;52(5):629-40 [15100240.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Mar 3;56(4):459-80 [14969753.001]
  • [Cites] Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S189-99 [16113096.001]
  • [Cites] Mol Genet Metab. 1998 Jul;64(3):193-7 [9719628.001]
  • [Cites] Am J Surg. 2006 Nov;192(5):644-8 [17071200.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 8):7-10 [16360005.001]
  • [Cites] Oncologist. 2006 Oct;11(9):973-80 [17030637.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3056s-3058s [10541343.001]
  • (PMID = 17960470.001).
  • [ISSN] 0724-8741
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylamides; 0 / Wheat Germ Agglutinins; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


10. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histiocytic sarcoma is a rare malignant neoplasm that occurs in lymph nodes, skin, and the gastrointestinal tract.
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Binucleated cells were common, and 6 cases contained tumor giant cells.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • At the last follow-up, 2 patients have died of disseminated disease, 4 and 5 months following initial diagnosis.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.
  • Metastatic carcinoma, metastatic melanoma, and large cell non-Hodgkin lymphomas should be excluded by immunohistochemistry.
  • Tumor size may be a prognostic factor.

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Sakakibara T, Kurasawa T, Narumi K, Kamano T, Tsurumaru M: T-cell malignant lymphoma of the ileum causing ileac fistulas: report of a case. Surg Today; 2002;32(6):536-40
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell malignant lymphoma of the ileum causing ileac fistulas: report of a case.
  • We herein present a rare case of three fistulas caused by a recurrence of T-cell lymphoma of the ileum.
  • Upper and lower gastrointestinal examinations did not reveal any abnormal findings, but an abdominal aortic aneurysm was diagnosed by computed tomography, and thus was determined to be the source of the pain.
  • The patient was referred to our hospital to undergo a grafting operation; however, a laparotomy performed in July 1997 revealed an unexpected small intestinal tumor, and therefore a partial ileectomy between 15 and 70cm in an oral direction from the terminal ileum was carried out instead.
  • Histopathological and genetic examinations demonstrated diffuse small malignant lymphocytic T-cell lymphomas of the ileum invading all layers.
  • Metastasis of the facial skin and local recurrence were recognized 5 months later, and chemotherapy with THP-COP and ESHAP only resulted in progressive disease.
  • An autopsy revealed three fistulas caused by metastatic tumors, one of which communicated with the duodenum from the ileum, one with the skin from the ileum, and one to the transverse colon from the ileum.
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Male. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12107782.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 10
  •  go-up   go-down


12. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy.
  • CONTEXT: Malignant mixed Mullerian tumors are rare ovarian neoplasms that account for less than 2% of ovarian malignancies.
  • To our knowledge, this is the first report of a malignant mixed Mullerian tumor with metastasis to the pancreas.
  • The metastatic tumor was identified by endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and Trucut needle biopsy of the pancreas.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • EUS revealed an 11 cm cystic mass in the head of the pancreas that was characterized as a carcinosarcoma/malignant mesodermal mixed tumor by EUS-FNA and Trucut needle biopsy.
  • The tumor was morphologically identical to the surgical specimen of her ovarian mass.
  • The patient was treated with palliative chemotherapy and a three-month follow up CT scan did not reveal any new metastatic lesions.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
  • [MeSH-major] Mixed Tumor, Mullerian / secondary. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy, Fine-Needle / methods. Endosonography. Female. Humans. Neoplasm Staging. Pancreas / pathology. Pancreas / radiography. Prognosis. Tomography, X-Ray Computed


13. Nahas CS, Akhurst T, Yeung H, Leibold T, Riedel E, Markowitz AJ, Minsky BD, Paty PB, Weiser MR, Temple LK, Wong WD, Larson SM, Guillem JG: Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg Oncol; 2008 Mar;15(3):704-11
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation.
  • Choice of optimal treatment--neoadjuvant chemoradiation versus systemic chemotherapy alone--depends on accurate assessment of distant disease.
  • We prospectively evaluated the ability of [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) to detect distant disease in patients with locally advanced rectal cancer who were otherwise eligible for combined modality therapy (CMT).
  • Sites other than the rectum, mesorectum, or the area along the inferior mesenteric artery were considered distant and were divided into nine groups: neck, lung, mediastinal lymph node (LN), abdomen, liver, colon, pelvis, peripheral LN, and soft tissue.
  • A score greater than 3 was considered malignant.
  • Confirmation was based on tissue diagnosis, surgical exploration, and subsequent imaging.
  • Greatest accuracy was demonstrated in detection of liver (accuracy = 99.9%, sensitivity = 100%, specificity = 98.8%) and lung (accuracy = 99.9%, sensitivity = 80%, specificity = 100%) disease; PET detected 11/12 confirmed malignant sites in liver and lung.
  • All 10 were correctly staged by pre-CMT PET; abdominopelvic computed tomography (CT) scans accurately detected nine of them.
  • CONCLUSION: Baseline PET in patients with locally advanced rectal cancer reliably detects metastatic disease in liver and lung.
  • PET may play a significant role in defining extent of distant disease in selected cases, thus impacting the choice of neoadjuvant therapy.
  • [MeSH-major] Neoplasms, Multiple Primary / radionuclide imaging. Positron-Emission Tomography. Rectal Neoplasms / radionuclide imaging. Rectal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Staging. Prospective Studies. Single-Blind Method

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Surg Oncol. 2008 Apr;15(4):1265. Leibold, Tobias [added]
  • (PMID = 17882490.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / R01 82534-01
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


14. Ishii M, Iwai M, Harada Y, Kishida T, Asada H, Shin-Ya M, Itoh Y, Imanishi J, Okanoue T, Mazda O: Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver. Cancer Lett; 2007 Jan 8;245(1-2):134-43
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver.
  • Metastatic liver tumors are highly malignant and refractory to conventional therapies.
  • Co-administration of soluble TRAIL (sTRAIL) gene and ACD suppressed the metastatic liver tumors of CT-26, significantly inducing apoptosis in the tumors, while such effects were not demonstrated in mice that received either the sTRAIL gene or ACD alone.
  • The gene therapy of sTRAIL with a suboptimal dose of an anticancer drug is a new strategy for treatment of multiple liver metastasis.
  • [MeSH-major] Colonic Neoplasms / therapy. Dactinomycin / pharmacology. Liver Neoplasms / therapy. TNF-Related Apoptosis-Inducing Ligand / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / genetics. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / genetics. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Drug Synergism. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Humans. Mice. Microscopy, Fluorescence. Neoplasms, Experimental / genetics. Neoplasms, Experimental / pathology. Neoplasms, Experimental / therapy. Plasmids. Protein Synthesis Inhibitors / pharmacology. Solubility. Transfection

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16478647.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Protein Synthesis Inhibitors; 0 / TNF-Related Apoptosis-Inducing Ligand; 1CC1JFE158 / Dactinomycin
  •  go-up   go-down


15. Kinuya S, Kawashima A, Yokoyama K, Kudo M, Kasahara Y, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N: Anti-angiogenic therapy and radioimmunotherapy in colon cancer xenografts. Eur J Nucl Med; 2001 Sep;28(9):1306-12
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-angiogenic therapy and radioimmunotherapy in colon cancer xenografts.
  • Angiogenesis is critical to the growth and metastatic process of malignant tumors.
  • Experimental RIT with 4.63 MBq of 131I-A7, an IgG1 anti-colorectal monoclonal antibody, was conducted in mice xenografted with LS 180 human colon cancer cells.
  • 2-ME administration suppressed tumor growth and improved the efficacy of RIT in comparison to RIT alone.
  • Tumor volumes on day 13, expressed as a ratio relative to the initial volume, were 12.7 +/- 2.95 in the nontreated control, 4.73 +/- 0.89 with 2-ME, 3.05 +/- 0.37 with RIT and 0.97 +/- 0.20 with RIT+2-ME.
  • Immunohistochemistry of tumor sections stained with an antibody against factor VIII demonstrated a decrease in microvessel number within tumors treated with 2-ME (7.9 +/- 0.8/200x field) as compared with that in control tumors (29.9 +/- 2.5).
  • Cell proliferation assay at increasing concentrations of 2-ME showed direct cytotoxicity of 2-ME in vitro at 5 microM and greater.
  • The direct cytotoxicity of 2-ME appears to have contributed to this improvement.
  • Anti-angiogenic therapy may prolong the dormancy of microscopic metastases while RIT may exterminate this population of cells.
  • Therefore, the combined treatment may improve the therapeutic outcome of patients with disseminated cancer.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Colonic Neoplasms / radiotherapy. Estradiol / analogs & derivatives. Estradiol / therapeutic use. Radioimmunotherapy
  • [MeSH-minor] Animals. Antineoplastic Agents, Hormonal / therapeutic use. Cell Division / drug effects. Cell Survival / drug effects. Chemotherapy, Adjuvant. Female. In Vitro Techniques. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / pathology. Tumor Stem Cell Assay

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11585288.001).
  • [ISSN] 0340-6997
  • [Journal-full-title] European journal of nuclear medicine
  • [ISO-abbreviation] Eur J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents, Hormonal; 4TI98Z838E / Estradiol; 6I2QW73SR5 / 2-methoxyestradiol
  •  go-up   go-down


16. Curtis BR, Kaliszewski J, Marques MB, Saif MW, Nabelle L, Blank J, McFarland JG, Aster RH: Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol; 2006 Mar;81(3):193-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thrombocytopenia developing in the course of chemotherapy for malignant disease is usually attributed to drug-induced marrow suppression and/or marrow replacement by tumor.
  • We describe two patients who developed severe thrombocytopenia and hemorrhagic symptoms while being treated with oxaliplatin, 5-fluorouracil, and leukovorin for metastatic colon cancer in whom platelet destruction appears to have been caused by oxaliplatin-dependent antibodies specific for the platelet glycoprotein IIb/IIIa complex (alpha(IIb)/beta(3) integrin).
  • Drug-induced immune thrombocytopenia (DITP) should be considered in patients who experience a sudden, isolated drop in platelet levels while being treated with chemotherapeutic agents, especially when adequate numbers of megakaryocytes are present in the bone marrow.

  • Genetic Alliance. consumer health - Immune thrombocytopenia.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493620.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL013629; United States / NHLBI NIH HHS / HL / HL-13629
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Autoantibodies; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Lee SC, Wu CJ, Wu PY, Huang YL, Wu CW, Tao MH: Inhibition of established subcutaneous and metastatic murine tumors by intramuscular electroporation of the interleukin-12 gene. J Biomed Sci; 2003 Jan-Feb;10(1):73-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of established subcutaneous and metastatic murine tumors by intramuscular electroporation of the interleukin-12 gene.
  • Intramuscular EP of pIL-12 resulted in complete regression or substantial inhibition of 38C13 B-cell lymphoma, whereas pIL-12 delivered by gene gun or intramuscular injection without EP showed little therapeutic effect.
  • Impressive antitumor activity by intramuscular EP was also demonstrated in animals with advanced malignant disease.
  • At day 14 after 38C13 tumor inoculation, all animals were found to carry large tumors and to have metastases; without treatment, most died within a week.
  • Moreover, animals that were previously cured of 38C13 tumors by in vivo EP treatment significantly suppressed tumor growth when challenged 60 days later.
  • In vivo EP of the IL-12 gene was also effective in suppressing subcutaneous and lung metastatic tumors of CT-26 colon adenocarcinoma and B16F1 melanoma cells.
  • Together, these results show that intramuscular electrotransfer of the IL-12 gene may represent a simple and effective strategy for cancer treatment.
  • [MeSH-major] Genetic Therapy / methods. Interleukin-12 / administration & dosage. Neoplasm Metastasis / prevention & control. Neoplasms, Experimental / therapy
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Electroporation. Female. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Mice. Mice, Inbred Strains. Muscle, Skeletal. Survival Rate. Time Factors. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 National Science Council, ROC and S. Karger AG, Basel
  • (PMID = 12566989.001).
  • [ISSN] 1021-7770
  • [Journal-full-title] Journal of biomedical science
  • [ISO-abbreviation] J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 187348-17-0 / Interleukin-12
  •  go-up   go-down


18. Manuelli M, De Luca L, Iaria G, Tatangelo P, Sforza D, Perrone L, Bellini MI, Angelico R, Anselmo A, Tisone G: Conversion to rapamycin immunosuppression for malignancy after kidney transplantation. Transplant Proc; 2010 May;42(4):1314-6
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Malignancies are a well-known complication of immunosuppressive therapy among renal transplant recipients, representing an important cause of long-term morbidity and mortality.
  • Rapamycin has been shown to limit the proliferation of a number of malignant cell lines in vivo and in vitro.
  • METHODS: Fifteen patients developed the following malignancies at a mean of 90.3 months (range = 10-252) after kidney transplantation: metastatic gastric cancer (n = 1), metastatic colon cancer (n = 1), bilateral nephrourothelioma (n = 1), skin cancer (n = 2), Kaposi's sarcoma (n = 2), posttransplant lymphoproliferative disorder (PTLD; n = 4), renal cell carcinoma T1 (n = 1), MALT lymphoma (n = 1), intramucous colon carcinoma (n = 1), liposarcoma of the spermatic cord (n = 1).
  • After the diagnosis of malignancy, the patients were switched from calcineurin inhibitor-based immunosuppression to rapamycin (monotherapy, n = 3), or associated with steroids (n = 6) or with mycophenolate mofetil (n = 6).
  • RESULTS: Both patients with metastatic cancer underwent chemotherapy but succumbed after 6 and 13 months.
  • Two patients with PTLD who underwent chemotherapy died after 12 and 36 months.
  • Renal graft function remained stable in all other patients from diagnosis throughout follow-up.
  • Nevertheless, it is difficult to assess whether tumor regression was due to rapamycin treatment or to the reduced immunosuppression.
  • [MeSH-major] Kidney Transplantation / immunology. Neoplasms / immunology. Sirolimus / therapeutic use
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor. Colonic Neoplasms / immunology. Colonic Neoplasms / pathology. Genital Neoplasms, Male / immunology. Genital Neoplasms, Male / pathology. Humans. Immunosuppression / methods. Immunosuppressive Agents / therapeutic use. Liposarcoma / immunology. Liposarcoma / pathology. Male. Neoplasm Metastasis. Skin Neoplasms / immunology. Skin Neoplasms / pathology. Stomach Neoplasms / immunology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Inc.
  • (PMID = 20534289.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


19. Marshall JC, Fernandes BF, Di Cesare S, Maloney SC, Logan PT, Antecka E, Burnier MN Jr: The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis; 2007 Sep;28(9):2053-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma.
  • The expression of cyclooxygenase-2 (COX-2) has been reported as an indicator of poor prognosis in a wide variety of human tumors, including colon, breast and uveal melanoma (UM).
  • COX-2 inhibitors have shown promise in controlling the malignancy of several types of tumors.
  • Intraocular tumor growth was evaluated weekly by fundoscopic examination and each animal was weighed prior to examination.
  • Blood samples were taken weekly from all rabbits to detect circulating malignant cells (CMCs) throughout the experiment.
  • The control group developed more intraocular tumors and presented with metastases and higher detectable levels of CMCs before the treated group.
  • [MeSH-major] Benzeneacetamides / therapeutic use. Cyclooxygenase 2 Inhibitors / therapeutic use. Melanoma / drug therapy. Phenylacetates / therapeutic use. Uveal Neoplasms / drug therapy
  • [MeSH-minor] Animals. Models, Animal. Neoplasm Metastasis. Rabbits

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434930.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzeneacetamides; 0 / Cyclooxygenase 2 Inhibitors; 0 / Phenylacetates; 0J9L7J6V8C / nepafenac
  •  go-up   go-down


20. Cambien B, Karimdjee BF, Richard-Fiardo P, Bziouech H, Barthel R, Millet MA, Martini V, Birnbaum D, Scoazec JY, Abello J, Al Saati T, Johnson MG, Sullivan TJ, Medina JC, Collins TL, Schmid-Alliana A, Schmid-Antomarchi H: Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer; 2009 Jun 2;100(11):1755-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism.
  • Recent research has indicated that CXCR3/chemokines interactions that orchestrate haematopoetic cell movement are implicated in the metastatic process of malignant tumours, including that of CRC cells to lymph nodes.
  • In vivo, systemic CXCR3 antagonism by preventive or curative treatments with AMG487 markedly inhibited the implantation and the growth of human and mouse CRC cells within lung without affecting that in the liver.
  • Altogether, our findings indicate that activation of CXCR3 receptors by its cognate ligands facilitates the implantation and the progression of CRC cells within lung tissues and that inhibition of this axis decreases pulmonary metastasis of CRC in two murine tumour models.
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Cell Movement. Humans. Ligands. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Mice. Neoplasm Transplantation. Organ Specificity. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 15;95(2):627-32 [10627472.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):909-13 [12792744.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):409-18 [11310833.001]
  • [Cites] Arthritis Rheum. 2001 May;44(5):1022-32 [11352233.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1832-7 [11912162.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):2812-24 [12960302.001]
  • [Cites] Immunol Lett. 2004 Mar 29;92(1-2):171-8 [15081542.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4010-7 [15173015.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):540-50 [15229479.001]
  • [Cites] J Exp Med. 1993 Sep 1;178(3):1057-65 [8350046.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13791-6 [8943014.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):963-9 [9064356.001]
  • [Cites] J Clin Invest. 1998 Feb 15;101(4):746-54 [9466968.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] J Bone Miner Res. 2005 Feb;20(2):318-29 [15647826.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):490-7 [15701832.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2428-35 [15536145.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1743-50 [15755995.001]
  • [Cites] Life Sci. 2006 Mar 13;78(16):1784-93 [16263140.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7701-7 [16885372.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):357-71 [17016763.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):139-47 [17218951.001]
  • [Cites] Gut. 2007 Mar;56(3):365-72 [16870716.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3396-405 [17409450.001]
  • [Cites] J Immunother. 2007 Jul-Aug;30(5):490-8 [17589289.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4679-88 [17297455.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1652-8 [17894551.001]
  • [Cites] ChemMedChem. 2008 Jun;3(6):861-72 [18442035.001]
  • [Cites] Cancer Gene Ther. 2002 May;9(5):432-42 [11961666.001]
  • [Cites] Int J Cancer. 2002 May 1;99(1):149-53 [11948506.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2606-10 [11980656.001]
  • [Cites] J Invest Dermatol. 2002 Jun;118(6):915-22 [12060384.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] J Immunol. 2002 Nov 15;169(10):5546-54 [12421931.001]
  • [Cites] Hum Immunol. 2002 Dec;63(12):1164-71 [12480260.001]
  • [Cites] Hum Gene Ther. 2000 Jan 20;11(2):247-61 [10680839.001]
  • (PMID = 19436305.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ligands; 0 / Receptors, CXCR3
  • [Other-IDs] NLM/ PMC2695685
  •  go-up   go-down


21. Ohana P, Schachter P, Ayesh B, Mizrahi A, Birman T, Schneider T, Matouk I, Ayesh S, Kuppen PJ, de Groot N, Czerniak A, Hochberg A: Regulatory sequences of H19 and IGF2 genes in DNA-based therapy of colorectal rat liver metastases. J Gene Med; 2005 Mar;7(3):366-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulatory sequences of H19 and IGF2 genes in DNA-based therapy of colorectal rat liver metastases.
  • BACKGROUND: Malignant tumors of the liver are among the most common causes of cancer-related death throughout the world.
  • Current therapeutic approaches fail to control the disease in most cases.
  • This study seeks to explore the potential utility of transcriptional regulatory sequences of the H19 and insulin growth factor 2 (IGF2) genes for directing tumor-selective expression of a toxin gene (A fragment of diphtheria toxin), delivered by non-viral vectors.
  • METHODS: The therapeutic potential of the toxin vectors driven by the H19 and the IGF2-P3 regulatory sequences was tested in a metastatic model of rat CC531 colon carcinoma in liver.
  • RESULTS: Intratumoral injection of these vectors into colon tumors implanted in the liver of rats induced an 88% and a 50% decrease respectively in the median tumor volume as compared with the control groups.
  • This therapeutic action was accompanied by increased necrosis of the tumor.
  • Importantly, no signs of toxicity were detected in healthy animals after their treatment by the toxin expression vectors.
  • CONCLUSIONS: DT-A was preferentially expressed in liver metastases after being transfected with H19 or IGF2-P3 promoter-driven DT-A expression plasmids, causing a very significant inhibition of tumor growth as a result of its cytotoxic effect.
  • Our findings strongly support the feasibility of our proposed therapeutic strategy, which may contribute to open new gene therapeutic options for human liver metastases.
  • [MeSH-major] Colorectal Neoplasms. DNA / metabolism. Genetic Therapy / methods. Liver Neoplasms / secondary. Proteins / genetics. RNA, Untranslated / genetics. Regulatory Sequences, Nucleic Acid
  • [MeSH-minor] Animals. Disease Models, Animal. Genes, Reporter. Humans. Insulin-Like Growth Factor II. Male. Neoplasm Metastasis. RNA, Long Noncoding. Rats. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 John Wiley & Sons, Ltd.
  • (PMID = 15521051.001).
  • [ISSN] 1099-498X
  • [Journal-full-title] The journal of gene medicine
  • [ISO-abbreviation] J Gene Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / H19 long non-coding RNA; 0 / IGF2 protein, human; 0 / Proteins; 0 / RNA, Long Noncoding; 0 / RNA, Untranslated; 67763-97-7 / Insulin-Like Growth Factor II; 9007-49-2 / DNA
  •  go-up   go-down


22. Yeg├╝ez JF, Martinez SA, Sands DR, Sands LR, Hellinger MD: Colorectal malignancies in HIV-positive patients. Am Surg; 2003 Nov;69(11):981-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to the development of more effective medications, those infected with HIV are living longer.
  • A retrospective review of HIV/AIDS patients with colorectal malignant tumors was undertaken.
  • We included adult patients, with ELISA and Western blot test positive for HIV, and primary malignant tumors located in the colon or rectum.
  • Malignant neoplasms of the anus were excluded for the purposes of this study.
  • Twelve patients (9 males and 3 females), mean age 41 years, were identified with the following neoplasm: 6 adenocarcinomas (ACA), 5 non-Hodgkin lymphomas (NHL), and 1 small-cell carcinoma.
  • Intravenous drug abuse was the main risk factor for HIV.
  • No patient had identified risk factors for colorectal neoplasm.
  • Five out of six patients with ACA had metastatic disease at the time of diagnosis.
  • One patient with stage II ACA developed early liver metastases after colonic resection.
  • These patients developed tumors at earlier ages and were diagnosed at an advanced stage.
  • The use of the new antiretroviral therapy regimens should be further evaluated to know its impact in the survival.


23. Tamaskar I, Mekhail T, Dreicer R, Olencki T, Roman S, Elson P, Bukowski RM: Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease. Invest New Drugs; 2008 Dec;26(6):553-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
  • Temozolomide is an alkylating agent which crosses the blood brain barrier and has demonstrated antitumor activity against a broad range of tumor types, including malignant glioma, melanoma, non small cell lung cancer and carcinoma of the ovary and colon.
  • A Phase I trial was conducted to determine the toxicity of this combination in refractory solid tumor patients.
  • METHODS: Twenty five patients with metastatic cancers were enrolled in a Phase I dose escalation trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Metastasis. Survival Rate. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1998 Oct;25(5 Suppl 12):32-4 [9865710.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1377-82 [17416857.001]
  • [Cites] Cancer Treat Rev. 1997 Jan;23 (1):35-61 [9189180.001]
  • [Cites] Invest New Drugs. 1994;12(3):169-82 [7896535.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):98-103 [12468349.001]
  • [Cites] Clin Lung Cancer. 2002 May;3(4):254-8 [14662033.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18):4845-52 [1680023.001]
  • [Cites] Br J Cancer. 1992 Feb;65(2):287-91 [1739631.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1455-61 [18300256.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8389-95 [16293869.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):90-6 [15598944.001]
  • [Cites] Cancer Res. 1998 Oct 1 ;58(19):4363-7 [9766665.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):309-17 [10037179.001]
  • [Cites] N Engl J Med. 1995 Apr 13;332(15):1004-14 [7885406.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):203-7 [12675312.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):5846-52 [3664486.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):910-3 [7707118.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):420-5 [11786569.001]
  • [Cites] Br J Cancer. 1999 Nov;81(6):1022-30 [10576660.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):1996-2004 [15558071.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] Anticancer Drugs. 1997 Jan;8(1):92-7 [9147618.001]
  • [Cites] Clin Cancer Res. 1997 Jul;3(7):1093-100 [9815788.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):61-5 [15719277.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):742-7 [10762746.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1212-9 [10715290.001]
  • (PMID = 18626572.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


24. Wolpin BM, Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology; 2008 May;134(5):1296-310
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic treatment of colorectal cancer.
  • Over the past 12 years, significant progress has been made in the systemic treatment of this malignant condition.
  • Six new chemotherapeutic agents have been introduced, increasing median overall survival for patients with metastatic colorectal cancer from less than 9 months with no treatment to approximately 24 months.
  • For patients with stage III (lymph node positive) colon cancer, an overall survival benefit for fluorouracil-based chemotherapy has been firmly established, and recent data have shown further efficacy for the inclusion of oxaliplatin in such adjuvant treatment programs.
  • For patients with stage II colon cancer, the use of adjuvant chemotherapy remains controversial, but may be appropriate in a subset of individuals at higher risk for disease recurrence.
  • Ongoing randomized clinical trials are evaluating how best to combine currently available therapies, while smaller studies are evaluating new agents, with the goal of continued progress in prolonging life among patients with metastatic colorectal cancer and increasing cure rates among those with resectable disease.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2006 Feb;17(2):239-45 [16344278.001]
  • [Cites] Invest New Drugs. 2005 Dec;23(6):539-45 [16267624.001]
  • [Cites] N Engl J Med. 2006 Mar 2;354(9):980-2; discussion 980-2 [16510760.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2059-64 [16648506.001]
  • [Cites] Anticancer Drugs. 2006 Aug;17(7):855-7 [16926635.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]
  • [Cites] J Clin Oncol. 2007 Jan 10;25(2):180-6 [17210937.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2205-11 [17470850.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2198-204 [17470851.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3230-7 [17664471.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3238-45 [17664472.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3392-4 [17687146.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3456-61 [17687149.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4664-6 [17699842.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4224-30 [17548839.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4217-23 [17548840.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4165-7 [17709796.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4557-61 [17876013.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4575-80 [17925551.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4779-86 [17947725.001]
  • [Cites] Lancet. 1995 Feb 11;345(8946):349-53 [7845115.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 15;87(22):1686-93 [7473817.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2936-43 [8523058.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):294-9 [8674006.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):300-3 [8674007.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):808-15 [9053508.001]
  • [Cites] J Natl Cancer Inst. 1997 Apr 2;89(7):497-505 [9086006.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):1049-51 [9402181.001]
  • [Cites] Acta Oncol. 1998;37(3):285-9 [9677101.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2739-44 [9704726.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3461-75 [9779725.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1413-8 [9807987.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1053-71 [9834817.001]
  • [Cites] Eur J Cancer. 1998 Sep;34(10):1509-13 [9893621.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1336-8 [10334516.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):476-87 [15689586.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):641-61 [11895891.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2106-13 [11966385.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1160-7 [12165641.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3605-16 [12202661.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3617-27 [12202662.001]
  • [Cites] Oncologist. 2002;7 Suppl 4:2-8 [12202782.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3992-8 [12351596.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):45-54 [12422313.001]
  • [Cites] Mol Cancer Ther. 2002 Jan;1(3):227-35 [12467217.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):60-5 [12506171.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3589-96 [12552961.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):413-20 [12560428.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3721-8 [12963704.001]
  • [Cites] Health Technol Assess. 2003;7(32):1-93 [14604497.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):166-74 [14701779.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1201-8 [14993230.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1209-14 [15051767.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1778-84 [14769855.001]
  • [Cites] N Engl J Med. 2007 Nov 15;357(20):2040-8 [18003960.001]
  • [Cites] Clin Colorectal Cancer. 2007 Nov;6(10):683-90 [18039421.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):374-9 [18202412.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):717-23 [17974556.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):674-80 [19179549.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1293-300 [12663717.001]
  • [Cites] J Natl Cancer Inst. 2003 May 21;95(10):708-16 [12759388.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2059-69 [12775730.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):295-300 [9440756.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):105-8 [9541691.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 5):4-12 [9609103.001]
  • [Cites] Cancer. 1978 Nov;42(5):2169-76 [363254.001]
  • [Cites] Surg Clin North Am. 1981 Dec;61(6):1311-20 [7031937.001]
  • [Cites] Surg Clin North Am. 1981 Dec;61(6):1321-9 [6171898.001]
  • [Cites] Ann Surg. 1984 Apr;199(4):375-82 [6370155.001]
  • [Cites] N Engl J Med. 1985 Jun 6;312(23):1465-72 [2859523.001]
  • [Cites] Br J Surg. 1985 May;72(5):359-63 [3888335.001]
  • [Cites] J Clin Oncol. 1985 Dec;3(12):1624-31 [2933492.001]
  • [Cites] N Engl J Med. 1986 Nov 13;315(20):1294-5 [3773947.001]
  • [Cites] Br J Surg. 1987 Jul;74(7):569-72 [3304518.001]
  • [Cites] Cancer. 1988 Mar 1;61(5):1018-23 [3338045.001]
  • [Cites] JAMA. 1988 Jun 24;259(24):3571-8 [3286920.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1407-18 [2476530.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1419-26 [2674331.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):425-32 [2404556.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] Arch Surg. 1990 Jul;125(7):897-901 [2369315.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1466-75 [2202789.001]
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] CA Cancer J Clin. 1992 Jan-Feb;42(1):19-38 [1728335.001]
  • [Cites] Semin Oncol. 1992 Apr;19(2 Suppl 3):10-5 [1532669.001]
  • [Cites] Lancet. 1992 Aug 29;340(8818):502-6 [1354275.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2454-60 [8095852.001]
  • [Cites] BMJ. 1993 Mar 20;306(6880):752-5 [7683942.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1819-25 [15774775.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):549-57 [15695501.001]
  • [Cites] N Engl J Med. 2005 May 5;352(18):1851-60 [15872200.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3502-8 [15908660.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3706-12 [15867200.001]
  • [Cites] Med Clin North Am. 2005 Jul;89(4):771-93 [15925649.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2435-46 [15880563.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4866-75 [15939922.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5235-46 [16051966.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1211-20 [16106026.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(14):2060-70 [16125380.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8671-8 [16314627.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]
  • [Cites] JAMA. 2005 Dec 7;294(21):2703-11 [16333005.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):136-47 [10623704.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Feb;14(1):17-23 [10680069.001]
  • [Cites] Tumour Biol. 2000 Mar-Apr;21(2):105-15 [10686540.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001545 [10796809.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343(13):905-14 [11006366.001]
  • [Cites] Semin Oncol. 2000 Oct;27(5 Suppl 10):72-7 [11049035.001]
  • [Cites] JAMA. 2000 Dec 20;284(23):3028-35 [11122590.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):157-63 [11134208.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] J Clin Epidemiol. 2001 Apr;54(4):359-66 [11297886.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2182-94 [11489791.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3895-902 [11559727.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] J Clin Oncol. 2001 Nov 1;19(21):4097-106 [11689577.001]
  • [Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1797-806 [15067028.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):317-9 [15269308.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3766-75 [15365073.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Cancer. 1975 Apr;35(4):1031-5 [1090358.001]
  • [Cites] Cancer. 1976 Oct;38(4):1461-7 [791471.001]
  • [Cites] Surg Gynecol Obstet. 1977 Oct;145(4):549-54 [331522.001]
  • [Cites] N Engl J Med. 1978 Aug 31;299(9):448-51 [683276.001]
  • (PMID = 18471507.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009172-34; United States / NCI NIH HHS / CA / IP50CA127003-01; United States / NCI NIH HHS / CA / CA009172-34; United States / NCI NIH HHS / CA / T32 CA009172; United States / NCI NIH HHS / CA / T32CA09001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / Prodrugs; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 182
  • [Other-IDs] NLM/ NIHMS58868; NLM/ PMC2528832
  •  go-up   go-down


25. Micke P, Ostman A: Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer; 2004 Aug;45 Suppl 2:S163-75
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?
  • Stroma cells, together with extracellular matrix components, provide the microenvironment that is pivotal for cancer cell growth, invasion and metastatic progression.
  • Characteristic stroma alterations accompany or even precede the malignant conversion of epithelial cells.
  • Seminal functional studies in various cancer types, including breast, colon, prostate and lung cancer, have confirmed the concept that fibroblasts can determine the fate of the epithelial cell, since they are able to promote malignant conversion as well as to revert tumour cells to a normal phenotype.
  • Finally, a laser-capture- and microarray-based approach is presented, which comprehensively characterises carcinoma-associated fibroblasts in their in vivo environment for the identification of potential targets for anti-cancer therapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Fibroblasts / drug effects. Fibroblasts / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Stromal Cells / pathology
  • [MeSH-minor] Animals. Epithelial Cells / drug effects. Epithelial Cells / pathology. Humans. Muscle Cells / drug effects. Muscle Cells / pathology. Neoplasm Invasiveness. Neoplasm Metastasis. Platelet-Derived Growth Factor / metabolism. Transforming Growth Factor beta / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15552797.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platelet-Derived Growth Factor; 0 / Transforming Growth Factor beta
  • [Number-of-references] 140
  •  go-up   go-down


26. Djeu JY, Wei S: Clusterin and chemoresistance. Adv Cancer Res; 2009;105:77-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resistance to anticancer agents is one of the primary impediments to effective cancer therapy.
  • Chemoresistance occurs not only to clinically established therapeutic agents but also to novel targeted therapeutics.
  • Both intrinsic and acquired mechanisms have been implicated in drug resistance but it remains controversial which mechanisms are responsible that lead to failure of therapy in cancer patients.
  • Its role has been documented in prostate cancer for paclitaxel/docetaxel resistance as well as in renal, breast, and lung tumor cells.
  • Moreover, it is abnormally upregulated in numerous advanced stage and metastatic cancers spanning prostate, renal, bladder, breast, head and neck, colon, cervical, pancreatic, lung carcinomas, melanoma, and lymphoma.
  • Resistance to targeted death-inducing molecules, tumor necrosis factor, Fas and TRAIL, or histone deacetylase inhibitors can also be mediated by sCLU.
  • Expression of sCLU may be an adaptive response to genotoxic and oxidative stresses but this adaptive response could pose a threat in malignant cells being treated with cytotoxic agents by enhancing their survival potential.
  • The actual mechanisms for sCLU induction are unclear but STAT1 is required for its constitutive upregulation in docetaxel-resistant tumor cells.
  • Thus, sCLU has a key role in preventing apoptosis induced by cytotoxic agents and has the potential to be targeted for cancer therapy.
  • [MeSH-major] Clusterin / physiology. Drug Resistance, Neoplasm. Neoplasms / drug therapy
  • [MeSH-minor] Drug Resistance, Multiple. Humans. Oxidative Stress

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2005 Jun;124(6):1300-7 [15955107.001]
  • [Cites] Nat Cell Biol. 2005 Sep;7(9):909-15 [16113678.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96 [16145049.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Mar;2(3):150-7 [16264908.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1837-49 [16373699.001]
  • [Cites] Biochem J. 2006 Apr 1;395(1):223-31 [16336210.001]
  • [Cites] Nat Clin Pract Oncol. 2006 May;3(5):269-80 [16683005.001]
  • [Cites] Urology. 2006 Sep;68(3):609-14 [16979705.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6113-22 [16652143.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):611-22 [17096323.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2278-87 [17148459.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):9-23 [17084534.001]
  • [Cites] Histopathology. 2007 Feb;50(3):331-7 [17257128.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Apr;4(4):236-44 [17392714.001]
  • [Cites] Neoplasia. 2001 Jul-Aug;3(4):360-7 [11571636.001]
  • [Cites] Mol Urol. 2001 Autumn;5(3):105-11 [11690557.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4245-52 [11751526.001]
  • [Cites] Prostate. 2002 Feb 15;50(3):179-88 [11813210.001]
  • [Cites] Cell Stress Chaperones. 2002 Jan;7(1):23-35 [11892985.001]
  • [Cites] Urology. 2002 Sep;60(3):516-20 [12350509.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3276-84 [12374699.001]
  • [Cites] Nat Cell Biol. 2003 Apr;5(4):320-9 [12652308.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4):372-80 [14508108.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38214-9 [12882985.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1834-42 [14996747.001]
  • [Cites] Mol Cancer Ther. 2004 Mar;3(3):223-32 [15026542.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2298-304 [14755245.001]
  • [Cites] Cell Cycle. 2009 Feb 1;8(3):473-81 [19177010.001]
  • [Cites] Eur J Cancer. 2009 Jul;45(10):1846-54 [19342222.001]
  • [Cites] Int J Cancer. 2009 Aug 15;125(4):791-806 [19391138.001]
  • [Cites] Oncogene. 2009 Sep 17;28(37):3307-19 [19597465.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):170-6 [10646870.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2547-54 [10811138.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1655-63 [10815883.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5907-12 [10823943.001]
  • [Cites] Blood. 2000 Jul 15;96(2):398-404 [10887098.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21055-60 [10770937.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):393-9 [10934144.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jan;280(1):G149-56 [11123208.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3869-76 [11358798.001]
  • [Cites] Urology. 2001 Aug;58(2 Suppl 1):39-49 [11502446.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3126-36 [15126350.001]
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2477-81 [15126879.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Prostate. 2004 Dec 1;61(4):318-23 [15389725.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Aug 31;147(1):196-203 [3632663.001]
  • [Cites] Biochem J. 1989 Jan 1;257(1):293-6 [2920020.001]
  • [Cites] Mol Cell Biol. 1989 Aug;9(8):3473-81 [2477686.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8577-81 [1924317.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6940-4 [1458483.001]
  • [Cites] J Cancer Res Clin Oncol. 1994;120(3):186-8 [8263017.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2431-7 [7757997.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):229-33 [9000560.001]
  • [Cites] J Biol Chem. 1997 Oct 17;272(42):26620-6 [9334243.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30777-84 [9804855.001]
  • [Cites] J Biol Chem. 1998 Nov 20;273(47):31068-74 [9813006.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1596-605 [17404365.001]
  • [Cites] ChemMedChem. 2007 Jul;2(7):920-42 [17530726.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1772(9):1103-11 [17689225.001]
  • [Cites] Mol Cancer Ther. 2007 Nov;6(11):2938-47 [18025278.001]
  • [Cites] Cell Cycle. 2007 Nov 15;6(22):2782-7 [17998803.001]
  • [Cites] Kidney Int. 2008 Mar;73(5):567-77 [18075502.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):527-32 [18177691.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1291-5 [18316546.001]
  • [Cites] J Biol Chem. 2008 May 9;283(19):12851-61 [18321852.001]
  • [Cites] J Urol. 2008 Aug;180(2):565-70; discussion 570 [18554663.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):48-59 [19118032.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):403-6 [19147550.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):708-13 [19147778.001]
  • [Cites] J Cell Mol Med. 2008 Dec;12(6B):2566-85 [19210756.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1707-11 [9815554.001]
  • [Cites] Prostate. 1999 May;39(2):87-93 [10221563.001]
  • [Cites] Eur J Biochem. 1999 Jul;263(2):534-42 [10406964.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):277-83 [15578711.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95 [15663992.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):14212-21 [15689620.001]
  • [Cites] J Cell Physiol. 2005 Aug;204(2):463-9 [15685647.001]
  • (PMID = 19879424.001).
  • [ISSN] 0065-230X
  • [Journal-full-title] Advances in cancer research
  • [ISO-abbreviation] Adv. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098080
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLU protein, human; 0 / Clusterin
  • [Number-of-references] 78
  • [Other-IDs] NLM/ NIHMS539156; NLM/ PMC3889866
  •  go-up   go-down


27. Srivastava K, Singh S, Srivastava M, Srivastava AN: Incisional skin metastasis of a squamous cell cervical carcinoma 3.5 years after radical treatment--a case report. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1183-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incisional skin metastasis of a squamous cell cervical carcinoma 3.5 years after radical treatment--a case report.
  • Metastatic carcinoma in an abdominal wall incision from internal malignant neoplasm is an uncommon and often a preterminal event.
  • Most commonly metastatic skin incisional cancers have been reported with cancers of colon, kidney, and bladder.
  • We report a postoperative case of squamous cell carcinoma cervix FIGO stage IIA in a patient who after 3.5 years of completion of radical treatment (postoperative external and intravaginal radiation therapy) developed incisional skin metastasis followed by extensive subcutaneous metastasis in the vulval region.
  • She received salvage chemotherapy; however, she did not show any response and finally succumbed to the disease.
  • The intent of treatment remains palliation either by radiation/chemotherapy/surgery alone or in combinations.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Fatal Outcome. Female. Fluorouracil / administration & dosage. Gynecologic Surgical Procedures. Humans. Radiotherapy


28. Moozar KL, Wong CS, Couture J: Anorectal malignant melanoma: treatment with surgery or radiation therapy, or both. Can J Surg; 2003 Oct;46(5):345-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anorectal malignant melanoma: treatment with surgery or radiation therapy, or both.
  • INTRODUCTION: Anorectal malignant tumours are increasing in frequency for unknown reasons.
  • Surgery is the principal treatment, and the role of adjuvant therapy has not been defined.
  • METHODS: We reviewed the charts of all registered patients with anorectal malignant melanoma (AMM) treated with surgery or radiotherapy, or both, at the hospital between 1980 and 1999, paying particular attention to survival, and local and distant recurrences.
  • RESULTS: There were 14 patients, all of whom were followed up to the time of death or for a minimum of 28 months for surviving patients.
  • The mean ages at diagnosis were 56 years for men and 68 years for women.
  • Clinical staging was as follows: local, 10 patients; locoregional, 3 patients and metastatic disease, 1 patient.
  • Local therapy included local resection alone in 7 cases and abdominoperineal resection in 7.
  • Seven patients received pelvic irradiation at some time during their disease, using different doses and fractionation schemes.
  • Three of them had concomitant chemotherapy and radiotherapy with no tumour regression.
  • Six patients were alive 1 year after treatment (median survival 32.5 mo [range from 21-51 mo]).
  • Eleven of the 12 patients who died had metastatic disease.
  • The overall survival was poor regardless of local treatment.
  • [MeSH-major] Anus Neoplasms / therapy. Melanoma / therapy. Rectal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colostomy. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Palliative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant. Reoperation. Time Factors

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trop Gastroenterol. 2000 Apr-Jun;21(2):86-7 [10881635.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):174-8 [8419240.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):18-25 [8988722.001]
  • [Cites] Eur J Surg Oncol. 1996 Dec;22(6):598-601 [9005147.001]
  • [Cites] Surg Oncol. 1996 Aug;5(4):165-8 [9067564.001]
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Cancer. 1998 Oct 15;83(8):1664-78 [9781962.001]
  • [Cites] Acta Oncol. 1998;37(5):497-9 [9831382.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1203-8 [10496563.001]
  • [Cites] Tumori. 2000 Jul-Aug;86(4):356-8 [11016729.001]
  • [Cites] Dis Colon Rectum. 1976 May-Jun;19(4):350-6 [1084261.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • [Cites] Br J Surg. 1981 Sep;68(9):667-8 [7272698.001]
  • [Cites] Surg Gynecol Obstet. 1982 Mar;154(3):337-41 [7064068.001]
  • [Cites] Dis Colon Rectum. 1982 Oct;25(7):693-703 [7128372.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):772-7 [7172945.001]
  • [Cites] Br J Surg. 1986 Jan;73(1):68-9 [3947881.001]
  • [Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]
  • [Cites] Arch Surg. 1990 Mar;125(3):313-6 [2306178.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • (PMID = 14577706.001).
  • [ISSN] 0008-428X
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3211713
  •  go-up   go-down


29. Catani M, De Milito R, Simi M: [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location]. Chir Ital; 2005 Jan-Feb;57(1):127-33
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location].
  • [Transliterated title] Nuovi orientamenti nella cura dei tumori stromali gastroenterici (GIST) avanzati e metastatici: trattamento combinato intervento chirurgico-terapia sistemica con imatinib in un caso a localizzazione primitiva gastrica.
  • Gastrointestinal stromal tumours (GIST) are rare neoplasms originating from connective tissue in the digestive tract with an incidence of less than 1% and account for most non-epithelial primitive digestive tumours.
  • Metastasis diagnosed at the time of disease discovery confirms GIST malignancy.
  • Resistance to conventional chemotherapy is commonly shown by malignant GIST.
  • Most patients with advanced malignant GIST achieve clinical benefit with imatinib mesilate, an orally administered selective inhibitor of the tyrosine kinase receptor.
  • At the time of the first operation the patient had lost 10 kg body weight over the previous months and was seriously cachectic.
  • Considering the action mechanism of imatinib and the extent of the lesion we decided to perform a total gastrectomy procedure.
  • At the time of the operation the stomach seemed to have a modified volume and shape: it appeared to be divided into two sacs, the larger and deeper of which was the original gastric cavity, while the superficial, smaller one seemed to be a protrusion of the organ.
  • The stomach was indistinguishable from the spleen, the transverse colon and the distal pancreatic tract.
  • The neoplasm was directly linked to the left liver and to the inferior diaphragmatic surface.
  • We performed total gastrectomy and resection of the tail of the pancreas, the spleen, and the transverse colon all in one and the same session.
  • The patient was discharged on postoperative day 8 and commenced imatinib therapy 30 days after the operation with 4 tablets per day.
  • One year after the operation the outcome appears to be lasting and the patient has tolerated the drug treatment well.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrectomy. Gastrointestinal Stromal Tumors / therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Benzamides. Humans. Imatinib Mesylate. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832750.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down






Advertisement